Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tara Gonzales"'
Autor:
Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV d
Externí odkaz:
https://doaj.org/article/6b66e6d3a8c14c57a799f9529b689f38
Autor:
Tara Gonzales, Aurore Bergamasco, Tiffany Cristarella, Camille Goyer, Matthew Wojdyla, Abiola Oladapo, John Sawicky, John Yee, Yola Moride
Publikováno v:
American Journal of Perinatology.
Objective Palivizumab is a humanized monoclonal antibody approved for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in infants and young children at high risk of RSV disease. This syste
Autor:
Nicole M. Zimmerman, Jaime Fergie, I. Winer, Mitchell Goldstein, Tara Gonzales, Adam Bloomfield, David Diakun, Amanda M. Kong, Leonard R. Krilov
Publikováno v:
American Journal of Perinatology.
Objective In 2014, the American Academy of Pediatrics (AAP) changed its policy on the use of respiratory syncytial virus immunoprophylaxis (RSV-IP) so that RSV-IP was no longer recommended for use among infants without other medical conditions born >
Publikováno v:
Journal of Medical Economics. 23:139-147
Aims: To examine healthcare resource utilization (HRU) and costs within 12 months after hospitalization for respiratory syncytial virus (RSVH) or unspecified bronchiolitis (UBH) in infants. Materials and methods: Infants born July 1, 2009–June 30,
Publikováno v:
The Journal of infectious diseases. 225(7)
Background In 2014, the American Academy of Pediatrics stopped recommending palivizumab to otherwise healthy 29–34 weeks’ gestational age (wGA) infants aged Methods A historical, observational cohort study was conducted to evaluate RSVH and BH in
Autor:
Ashley Howard, Jon P. Fryzek, Tara Gonzales, Mina Suh, Xiaohui Jiang, Jaime Fergie, Adam Bloomfield
Publikováno v:
Open Forum Infectious Diseases
Background The AAP, in 2014, stopped endorsing palivizumab for use in children with BPD/CLDP born at < 32 weeks’ gestational age (wGA) between the ages of 12 to 24 months not requiring medical support during the 6 months before the start of RSV sea
Autor:
Ashley Howard, Tara Gonzales, Mina Suh, Jon P. Fryzek, Adam Bloomfield, Jaime Fergie, Xiaohui Jiang
Publikováno v:
Open Forum Infectious Diseases
Background In 2014, the AAP stopped recommending palivizumab for use in children with hemodynamically significant CHD (hs-CHD) aged 12 to 24 months at the RSV season start. This analysis investigates the impact of the 2014 AAP policy on the contempor
Publikováno v:
Open Forum Infectious Diseases
Background In 2014, the AAP stopped recommending RSV immunoprophylaxis for otherwise healthy 29–34 wGA preterm infants. This study examined the risk of RSVH and BH among 29–34 wGA infants before the AAP policy change (November 1, 2010–March 31,
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations and risk varies by gestational age (GA). Healthcare utilization following early hospitalizations caused by RSV (RSVH) or unspecified bronchiolitis (UBH) is n
Autor:
Amanda M. Kong, Kimmie K. McLaurin, Robert A. Clifford, Melissa Pavilack, Sally W. Wade, Tara Gonzales
Publikováno v:
Infectious Diseases and Therapy
Introduction Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured